.jpg)
Indonesia's pharmaceutical industry is Southeast Asia's largest by production volume, with total sales exceeding USD 9 billion annually. The sector is served by over 200 manufacturers, led by state-owned BUMN enterprises (Kimia Farma, Bio Farma, Phapros) and private players. Pharmaceutical manufacturing carries specific environmental risks: active pharmaceutical ingredient (API) residues in wastewater with known ecotoxicological effects, solvent emissions from formulation processes, hazardous waste (B3) generation from manufacturing and QC activities, and significant energy and water consumption in production and cold chain operations.
The regulatory framework for pharmaceutical environmental management is tightening. BPOM and KLHK are increasing enforcement of B3 waste handling, wastewater treatment standards, and environmental management system requirements. Meanwhile, international pharmaceutical buyers and healthcare procurement agencies WHO, UNFPA, UNICEF — are enforcing environmental compliance as a qualification criterion for supplier registration. ESG considerations are gaining traction in healthcare sector investment: major pharmaceutical investors are requiring Scope 1/2/3 GHG disclosures, water risk reports, and anti-pollution program documentation. Indonesian pharma companies targeting export markets and institutional buyers must build credible environmental management systems.
.jpg)
.jpg)
.jpg)
Active pharmaceutical ingredients in untreated effluent carry recognized ecotoxicological risks and are subject to tightening KLHK discharge standards — and facilities without pharmaceutical-specific wastewater treatment face regulatory exposure and progressive loss of institutional buyer qualification.
Pharmaceutical manufacturing generates diverse hazardous waste streams with distinct regulatory requirements, and facilities that have not formalized their B3 management systems to current standards face BPOM and KLHK enforcement risk that can disrupt production and delay product registrations.
Cold chain HFC refrigerant leaks, clean room HVAC systems, and energy-intensive sterile manufacturing generate significant but typically unquantified GHG emissions — and companies without verified carbon baselines are excluded from the sustainable finance instruments that institutional pharmaceutical investors increasingly require.
Antasena 2, Gg. Antasena II, RT.03/RW.18, Tegal Weru, Sariharjo, Kec. Ngaglik, Kabupaten Sleman, Daerah Istimewa Yogyakarta
.png)
.jpg)
